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Co-administration of tadalafil and tamsulosin HCl in patients with benign prostate hyperplasia and 
erectile dysfunction is increasing in clinical settings. Development of fixed-dose combination (FDC) 
of tadalafil and tamsulosin HCl could contribute to improving patients’ adherence and treatment ef-
ficacy. We evaluated the pharmacokinetics and safety profiles of a newly developed fixed-dose com-
bination capsule of tadalafil 5 mg/tamsulosin HCl 0.4 mg in comparison with co-administration of 
each formulation in healthy volunteers under fasted and fed conditions. Two randomized, open-
label, single-dose, two-way, crossover studies were completed in 29 subjects under fasted condition, 
and 33 subjects under fed condition. Serial blood sample collection for PK analysis was conducted 
up to 72 hours after dosing, and PK parameters were calculated using non-compartmental analysis. 
Geometric mean ratios and 90% confidence intervals of the Cmax and AUClast were used to evaluate 
comparative bioavailability. In both fasted and fed condition studies, the bioequivalence was estab-
lished. The most common adverse drug reactions were orthostatic hypotension and headache with 
no statistical difference between treatment groups. All subjects with orthostatic hypotension recov-
ered at follow-up test. Although changes in vital signs from baseline were statistically significant, 
there were no subjects with systolic blood pressure < 90 mmHg and there were no clinically mean-
ingful signs or symptoms associated. FDC of tadalafil and tamsulosin HCl can be an alternative to 
co-administration of individual drugs for providing better compliance. Changes in blood pressure 
should be kept in mind when tadalafil and tamsulosin HCl are co-administered in clinical settings.
Introduction
  Benign prostatic hyperplasia (BPH) is the proliferation of 
smooth muscle and epithelial cells in prostatic tissue resulting 
in lower urinary tract syndrome (LUTS).[1,2] Garraway et al. 
reported that the prevalence of BPH was 25.3% in total 699 sub-
jects aged between forty and seventy and tended to increase as 
the age increased.[3,4] Erectile Dysfunction (ED) is defined as 
difficulty in gaining or keeping erected state enough to enjoy sex 
life.[5,6] LUTS is known as an independent risk factor of ED.[6]
Suggested pathophysiologic mechanisms of LUTS and ED are 
decrease in nitric oxide synthase/nitric oxide production and 
overactivity of sympathetic nervous system.[7] Clinical studies 
have shown the prevalence of BPH in ED patients was as high 
as 72.2-85.2%.[6,8] 
  Tamsulosin hydrochloride (HCl) is a strong inhibitor of al-
Received 19 Aug 2016
Revised  29 Nov 2016
Accepted 29 Nov 2016
Keywords
pharmacokinetics, 
tadalafil, 
tamsulosin HCl, 
fixed-dose combination 
pISSN: 2289-0882
eISSN: 2383-5427
O
R
IG
IN
A
L A
R
TICLE
Copyright © 2016 Translational and Clinical Pharmacology
 It is identical to the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/).
 This paper meets the requirement of KS X ISO 9706, ISO 9706-1994 and 
ANSI/NISO Z.39.48-1992 (Permanence of Paper).
Vol. 24, No.4, Dec 15, 2016
176
TCP 
Transl Clin Pharmacol
Pharmacokinetics and safety of tadalafil/tamsulosin HCl FDC
pha-1 adrenoreceptor in the urogenital system and has been 
used in the treatment of dysuria caused by BPH.[9] Tadalafil 
inhibits phosphodiesterase-5 and increases nitric oxide activity 
which in turn increases penile blood flow resulting in enhance-
ment of the erectile function.[10,11] Tadalafil also acts on the 
smooth muscle in urogenital system and reduces LUTS in 
patients with BPH. U.S. Food and Drug Administration also ap-
proved tadalafil for treating signs and symptoms of patients who 
are comorbid with both BPH and ED in 2011.[12] The signs 
and symptoms of detrusor overactivity and LUTS were im-
proved with concomitant therapy with tadalafil and tamulosin 
HCl without the difference in safety in previous studies. There 
was also improvement in signs or symptoms related with ED 
accompanied with the LUTS in the treatment group that both 
tadalafil and tamsulosin HCl were co-used.[13,14] Thus, co-
prescription of tadalafil and tamsulosin HCl is increasing. Based 
on these findings, the development of fixed-dose combination 
(FDC) of tadalafil and tamsulosin HCl can be justified with the 
expectation of improving patients’ adherence and treatment 
efficacy, especially in old aged patients with high incidence of 
BPH and ED.  
  We evaluated the pharmacokinetics and safety profiles of 
a newly developed tadalafil/tamsulosin HCl FDC capsule 
(HCP1303, Hanmi Pharmaceutical Co. Seoul, Korea) and com-
pared with concomitant administration of individual drugs 
under fasted and fed conditions. Studies under both conditions 
were conducted considering the food effect of tamsulosin HCl 
in previous study.[9]
Methods 
Subjects
  Healthy male volunteers who were aged between 19 and 50 
years, weighed at least 55 kg, and had body mass index between 
18.5 and 25.0 kg/m2 were enrolled. Subjects agreed, voluntarily 
signed the informed consent forms and went through screen-
ing procedures such as past medical history, physical examina-
tion, and laboratory assessments including hematology, blood 
chemistry, serology and urine drug screening. Subjects with the 
following criteria were excluded: a history of clinically signifi-
cant hypersensitivity reaction to drugs or foods, with a genetic 
problem such as galactose intolerance, a history of gastrointesti-
nal diseases which would affect the absorption of investigational 
drugs, positive results on a urine drug screening or serology 
test, with an orthostatic hypotension, ocular disorders includ-
ing cataract, priapism, cardiovascular disorders or a history of 
micturition syncope. The study participants were not allowed to 
take any prescription drugs or herbal medicines for 2 weeks pri-
or to the study drug administration, nor any over-the-counter 
drugs or dietary supplements for 1 week prior to the study drug 
administration. The participants were also refrained from con-
suming alcohol, caffeinated beverages, and grapefruit products, 
as well as smoking, during the studies.
Study Design
  Two clinical trials with the identical design were conducted 
independently either under fasted or fed condition. Both stud-
ies were as designed randomized, open-label, single-dose, two-
treatment, two-period, crossover. A total of 30 participants 
in the fasted condition study and 36 participants in the fed 
condition study were randomized and assigned to one of the 
two treatment sequences (test drug - reference drug, or refer-
ence drug - test drug). Because there was a previous report that 
showed increased coefficient of variation (CV) value in AUClast 
of tamsulosin HCl in fed state compared with fasted state, the 
sample size was increased in the fed study.[9] Each treatment 
period was separated by a 7-day washout period that was over 
five-fold longer than the previously reported terminal half-lives 
of tamsulosin HCl and tadalafil.[12,15] 
  These studies were approved by the Institutional Review Board 
of Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea. Studies were conducted in accordance with the 
principles of the Declaration of Helsinki and Good Clinical 
Practice and were approved by the Ministry of Food and Drug 
Safety.
Treatment and administration
  The treatments consisted of a single oral dose of test drug 
[tadalafil 5 mg/tamsulosin HCl 0.4 mg FDC capsule (Hanmi 
Pharmaceutical Co., Seoul, Korea)] and reference drugs 
[tadalafil 5 mg tablet (Cialis®, Eli Lilly Korea) and tamsulosin 
HCl 0.4 mg capsule (Hanmi Pharmaceutical Co., Seoul, Korea) 
co-administered].
  In the fasted condition study, all participants were kept fasted 
overnight for at least 10 hours and received one of the two treat-
ments as per the randomization schedule. In the fed condition 
study, all participants were kept fasted overnight for at least 10 
hours and were allowed to have high-fat meals (at least total 900 
kcal, at least 35 percent fat) 30 minutes prior to the administra-
tion of investigational products and then were given the study 
drugs. The composition of high-fat meal was decided based on 
the guidance for food effect bioavailability of sustained-release 
products issued by the Ministry of Food and Drug Safety 
(MFDS).[16] Fluid intake was prohibited for 1 hour before and 
after administration of investigational products. Lunch and din-
ner were provided about 4 hours and 10 hours after administra-
tion of investigational products, respectively.
Blood sample collection and analysis
  Serial blood samples were collected in anti-coagulated EDTA-
K2 tubes at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 5, 6, 7, 8, 
10, 12, 24, 36, 48 and 72 h after dosing in the fasting condition 
study, and at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 
8, 10, 12, 24, 36, 48 and 72 h in the fed condition study to as-
sess plasma tadalafil and tamsulosin HCl concentrations. Blood 
sampling points were determined considering Tmax and elimina-
tion half-life of tadalafil and tamsulosin HCl.[9] Sampling times 
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were modified in the fed study because food intake delayed the 
Tmax of tamsulosin HCl.[9] Samples were centrifuged for eight 
minutes at 4°C, 1800 g and stored below -70°C until analysis. 
Plasma concentrations of tadalafil were measured using ultra-
performance liquid chromatography tandem mass spectrom-
etry (UPLC-MS/MS). The linear calibration ranges were 1–500 
ng/ml in tadalafil and 0.2–100 ng/ml in tamsulosin HCl. The 
coefficient of variation (CV) represents overall precision of the 
tadalafil and tamsulosin HCl assay was below 20.0% for LLOQ 
and 15.0% for other upper concentrations for calibration. Plas-
ma concentrations of both tadalafil and tamsulosin HCl were 
analyzed by BioInfra Co., (Suwon, Korea).
Pharmacokinetic data assessment
  PK parameters were evaluated using a non-compartmental 
model of Phoenix® WinNonlin® software version 6.4 (Certara, 
St.Louis, MO, USA). Cmax and Tmax were determined directly 
from the observed values. The area under the curve from the 
time of dosing to the last measurable concentration (AUClast) 
was calculated using the linear trapezoidal method for ascend-
ing concentrations and the log trapezoidal method for descend-
ing concentrations. The terminal elimination rate constant (λz) 
was estimated by linear regression of the terminal portion of 
the log-transformed plasma concentrations-to-time profile. The 
AUC from the last dosing time extrapolated to infinity (AUCinf) 
was calculated by AUClast + Clast/λz, where Clast represents the last 
measurable concentration. 
Safety and tolerability assessments
  Safety and tolerability were evaluated throughout the study. 
The assessments included monitoring of all adverse events 
based on physical examinations, vital signs, 12 lead electrocar-
diograms, routine hematology, serum chemistry, urinalysis, 
and orthostatic hypotension tests. Subjects were instructed to 
notify the study physician and/or nurses of any adverse events 
that occurred during the study. All AEs reported by subjects or 
detected in assessments were recorded and the investigators de-
termined their relationship to the treatment.
Statistical analysis
  Descriptive statistics were provided for baseline demographics, 
PK parameters and safety data by sequence group or treatment 
group. Baseline demographics of the treatment sequences were 
evaluated with Student’s t-test using the IBM SPSS Statistics 
software version 23.0 (SPSS Incorporated, Chicago, IL, USA). 
To compare the PK parameters (AUClast and Cmax) between 
treatments, a general linear mixed effects model was developed 
using log-transformed data with period, sequence, and treat-
ment as fixed effects and subjects nested within sequence as a 
random effect. The geometric mean ratio (GMR) and its 90% 
confidence interval (CI) of the AUClast and the Cmax between the 
FDC and co-administration of individual drugs were calculated, 
and the bioequivalence was demonstrated when the 90% CI en-
tirely fell within the conventional bioequivalence range of 0.8-
1.25. The incidence of major anticipated adverse drug reactions 
(ADRs) was statistically compared between treatment groups 
using chi-square test or McNemar’s test using the IBM SPSS 
Statistics software version 23.0 (SPSS Incorporated, Chicago, IL, 
USA). Changes in systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) from baseline were compared between 
treatment groups using repeated mixed effects model.
Results
 
Demographics
  A total of 31 subjects were enrolled in the fasted condition 
study. Two subjects withdrew consent during the study due to 
personal reasons, and 29 subjects completed the study and were 
included in the PK analysis. A total of 30 subjects who received 
at least one dose of any investigational products were included 
in the safety analysis. In the fed condition study, a total of 36 
subjects were enrolled. One subject was removed from the study 
due to poor adherence before administration of any investiga-
tional products. Two subjects withdrew consent at the end of 
period 1 due to personal reasons. As a result, 33 subjects in total 
completed the study, but there was a subject whose pre-dose 
concentration at period 2 was higher than 5% of Cmax, so 32 
subjects were included in the PK analysis. A total of 35 subjects 
who received at least one dose of any investigational products 
were included in the safety analysis. Baseline demographics 
were similar and showed no statistical difference between se-
quence groups in both studies. The demographic information of 
study subjects was summarized in Table 1.
Pharmacokinetics
Bioequivalence in the fasted and fed condition studies
  PK parameters and the plasma concentration-time profiles of 
tadalafil and tamsulosin HCl in the fasted condition study are 
shown in Table 2 and Figure 1, respectively. A single oral dose of 
tadalafil and tamsulosin HCl as the fixed-dose combination and 
the co-administration of individual drugs were bioequivalent. 
The GMRs (90% CI) of AUClast and Cmax between the test and 
the reference formulation of tadalafil were 0.98 (0.93–1.03) and 
0.99 (0.92–1.07). Similarly the values were 1.03 (0.98–1.09) and 
1.02 (0.96–1.08) for tamsulosin HCl, respectively. Furthermore, 
other PK parameters, including Tmax, AUCinf, t1/2, Vd/F and CL/
F were also comparable between the two treatments.
  PK parameters and the plasma concentration-time profiles 
of tadalafil and tamsulosin HCl in the fed condition study are 
shown in Table 2 and Figure 2, respectively. Single oral dose of 
tadalafil and tamsulosin HCl as the fixed-dose combination and 
the co-administration of individual drugs were bioequivalent. 
The GMRs (90% CI) of AUClast and Cmax between the test and 
the reference formulation of tadalafil were 0.99 (0.95–1.03) and 
0.95 (0.91–1.00). The values were 0.99 (0.94–1.05) and 1.02 
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(0.96–1.09) for tamsulosin HCl. Other PK parameters, includ-
ing Tmax, AUCinf, t1/2, Vd/F and CL/F were also comparable be-
tween the two treatments.
Post hoc cross-study evaluation of food effect on FDC 
  Post hoc evaluation of food effect on FDC was conducted using 
the same statistical method to assess the bioequivalence because 
both studies were performed in healthy male volunteers with 
the same design, used the same analytical methods although 
both studies were not specifically designed to be compared. The 
results are summarized in Table 3. Tmax of both tadalafil and 
tamsulosin HCl were delayed under fed condition compared to 
fasted condition. AUClast of tadalafil under the fed condition was 
increased by 16% compared to those under the fasted condition. 
However, AUClast of tamsulosin HCl was decreased by 24% un-
der fed condition compared to fasted condition. Cmax of tadalafil 
Variables
Fasted Study Fed Study
T-R (N=15) R-T (N=15) P-value T-R (N=17) R-T (N=18) P-value
Age (years) 24.5 ± 4.3 24.9 ± 3.5 0.82 27.0 ± 5.7 30.9 ± 6.5 0.07
Height (cm) 175.1 ± 4.8 175.5 ± 5.8 0.52 176.2 ± 5.2 174.7 ± 4.5 0.84
Weight (kg) 67.7 ± 6.0 69.1 ± 5.4 0.84 70.0 ± 4.9 70.4 ± 6.6 0.37
BMI (kg/m2) 22.0 ± 1.8 22.4 ± 1.7 0.59 22.5 ± 1.1 23.0 ± 1.7 0.29
Table 1. Demographics of study participants
Notes: Data are summarized as arithmetic mean ± standard deviation. P-values were derived by Student’s t-test. T-R, FDC followed by concomitant 
administration of individual drugs; R-T, concomitant administration of individual drugs followed by FDC
Figure 2. Plasma concentration-time profiles for (A) tadalafil, (B) tam-
sulosin HCl in fed condition study as a fixed-dose combination or con-
comitant administration of individual drugs. Data are shown as mean ± 
SD. FDC, fixed-dose combination; Reference, concomitant administra-
tion of individual drugs.
B
A
Figure 1. Plasma concentration-time profiles for (A) tadalafil, (B) 
tamsulosin HCl in fasted condition study as a fixed-dose combination 
or concomitant administration of individual drugs. Data are shown as 
mean ± SD. FDC, fixed-dose combination; Reference, concomitant 
administration of individual drugs.
A
B
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Table 4. The incidence of common adverse drug reactions
Adverse Drug Reaction Treatment Fasted Study Fed Study Total P-value#
Orthostatic hypotension
FDC
Reference
8/30 (26.7%)
7/29 (24.1%)
3/34 (8.8%)
4/34 (11.8%)
11/64 (17.2%)
11/63 (17.5%)
0.059
Total* 12/30 (40.0%) 6/35 (17.1%)
Headache
FDC
Reference
3/30 (10.0%)
2/29 (6.9%)
2/34 (5.9%)
4/34 (11.8%)
5/64 (7.8%)
6/63 (9.5%)
0.659
Total* 4/30 (13.3%) 6/35 (17.1%)
Dizziness
FDC
Reference
0/30
0/29
1/34 (2.9%)
1/34 (2.9%)
1/64 (1.6%)
1/64 (1.6%)
0.999
Total* 0/30 2/35(5.7%)
Notes: the number of subjects with ADRs / total subjects (percentage). P-values were derived by chi-square test. *Subjects whose ADRs occurred in 
both treatment groups were counted once. #Statistical difference in the incidence of ADRs between studies in fixed-dose combination group was esti-
mated.
under fed condition was similar to those in fasted condition. On 
the other hand, Cmax of tamsulosin HCl under the fed condition 
was 33% lower than the fasted condition.
Safety
Adverse events
  The number of subjects included in the safety analysis set (the 
number of subjects who administered at least 1 dose of investi-
gational products) was 30 in the fasted condition study and 35 
in the fed condition study. A total of 24 AEs were reported by 
15 subjects (50.0%) in the fasted condition study, and 30 AEs 
reported by 17 subjects (48.6%) in the fed condition study. AE 
profiles were similar for the FDC capsule and the co-adminis-
tration of individual drugs in each of the fasted and fed condi-
tion studies. All AEs were mild or moderate in severity, and 
there were no deaths, serious AEs (SAEs), or withdrawals due to 
AEs. 
  AEs reported after administration of investigational prod-
ucts were generally consistent with the known safety profile 
of tadalafil tablet and tamsulosin HCl capsule. Orthostatic 
hypotension and headache were the most common AEs. Other 
Parameter
Tadalafil Tamsulosin HCl
Fasted Study
(N=29)
Fed Study
(N=32)
Fed/Fasted Geo-
metric Mean Ratio 
(90% CI)
Fasted Study
(N=29)
Fed Study
(N=32)
Fed/Fasted Geo-
metric Mean Ratio 
(90% CI)
Tmax (h) 1.0 [0.5-4.5] 4.0 [2.0-5.6] 4.5 [3.0-6.0] 5.0 [3.0-7.0]
Cmax (ng/ml) 103.80 ± 25.99   91.13 ± 15.48 0.89 (0.81-0.97) 15.38 ± 3.74 10.43 ± 3.37 0.67 (0.59-0.75)
AUClast (ng∙h/ml) 1835.35 ± 442.93 2144.83 ± 626.33 1.16 (1.03-1.30) 185.96 ± 62.01 144.20 ± 61.90 0.76 (0.65-0.88)
AUCinf (ng∙h/ml) 2005.80 ± 589.04 2485.43 ± 930.43 193.54 ± 64.56 152.14 ± 64.12
t1/2 (h) 18.82 ± 5.61 22.43 ± 7.08  11.55 ± 2.87 12.47 ± 3.18
CL/F (L/h) 2.70 ± 0.79 2.28 ± 0.81 2.30 ± 0.77 3.03 ± 1.11
Vd/F (L)   69.51 ± 14.69 67.33 ± 11.29 35.98 ± 7.92 52.40 ± 19.91
Table 3. Comparison of pharmacokinetic parameters of tadalafil and tamsulosin HCl after a single oral administration as a fixed-dose combination 
capsule in the fasted and fed conditions
Notes: Data are summarized as arithmetic mean ± standard deviation except for Tmax, for which median [min-max] is presented.
Abbreviations: CI, confidence interval; Tmax, time to Cmax; Cmax, the maximum concentration of drug; AUClast, area under the plasma concentration-
time curve from the time of dosing to the last measurable concentration; AUCinf, area under the plasma concentration-time curve from dosing time 
extrapolated to infinity; t1/2, elimination half-life; CL/F, apparent clearance; Vd/F, apparent volume of distribution
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AEs were epigastric discomfort in fasted study, and dizziness 
(including postural dizziness), paresthesia, sinus pain, increased 
creatinine phosphokinase and nasal congestion in fed study. The 
number of subjects with orthostatic hypotension was similar 
between treatment groups in both studies (Table 4). Although 
the number of subjects with orthostatic hypotension seemed 
different for the FDC between fasted and fed conditions, the 
difference analyzed with chi-square test was not statistically sig-
nificant (p-value = 0.059). The durations of orthostatic hypoten-
sion were transient in all cases and there was no subject whose 
orthostatic hypotension remained at the follow-up test. 
Changes in vital signs
  SBP did not increase or decrease over time in both studies. In 
the fasted study, the mean DBP in sitting position decreased 
maximally at 8 h after dosing by 8.1 mmHg compared with the 
baseline (pre-dose). The maximum decrease in the mean DBP 
was 14.7 mmHg and occurred 3 hours after dosing in the fed 
study (Fig. 3 and 4). Considering the mechanisms of action of 
tadalafil and tamsulosin HCl, this effect could be anticipated 
with the investigational products. Additionally, physiological 
effect due to keeping in bed-rested state and restricted physical 
activity could be considered for another reason. Although the 
change of DBP from baseline was statistically significant in both 
studies, the decrease was not judged to be clinically significant 
because there were no symptom and sign related to the changes 
of DBP.  SBP and DBP had started to bounce back up from eight 
hours after dosing and stabilized to the baseline values in both 
studies. Other changes of vital signs could be explained with 
physiological effect due to restricted physical activity and diur-
nal variation. There were no statistically significant differences 
in vital signs between treatment groups in both studies.
Discussion 
  These studies were designed to evaluate the bioequivalence 
between FDC capsule of tadalafil 5 mg and tamsulosin HCl 0.4 
mg to the co-administration of individual drugs in fasted and 
fed conditions respectively. The analysis of PK parameters in 
these two studies demonstrated that the FDC is pharmacoki-
netically comparable to the concomitant administration of each 
drug in fasted and fed condition, showing that the GMR and its 
90% CI for FDC and concomitant administration of individual 
drugs falling entirely within the bioequivalence range (0.8–1.25). 
Other PK parameters of FDC were also pharmacokinetically 
comparable to those of concomitant administration of indi-
vidual drugs.
  Food affected the extent of exposure of tamsulosin HCl. Com-
paring with fasted condition, the Cmax of tamsulosin HCl in fed 
condition decreased by 32% in FDC and the AUClast decreased 
by 24% in FDC. These results of FDC were quite similar with 
Byung Hak Jin, et al.
Figure 4. Changes in (A) systolic blood pressure, (B) diastolic blood 
pressure over time in fed condition study. Data are shown as mean 
± SD. R, concomitantly administrated as individual drugs; T, adminis-
tered as a fixed-dose combination
B
A
Figure 3. Changes in (A) systolic blood pressure, (B) diastolic blood 
pressure over time in fasted condition study. Data are shown as mean 
± SD. R, concomitantly administrated as individual drugs; T, adminis-
tered as a fixed-dose combination
B
A
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the published data about fed condition study of tamsulosin HCl 
in which the Cmax decreased by 41% and the AUClast decreased 
by 24% under fed condition.[9] Our study showed that food 
increases slightly the variability in the exposure of tamsulosin 
HCl, which was demonstrated by AUCinf (intra-subject CV of 
AUCinf: 13% in fed study vs. 11% in fasted study). On the other 
hand, Cmax and AUClast of tadalafil in FDC under fasted and fed 
conditions were not within bioequivalence range. The result was 
conflicting with that of the previous study that tadalafil can be 
taken regardless of food.[12]
  FDC capsule also showed comparable safety profile to the con-
comitant administration of each drug. Orthostatic hypotension 
is an adverse event that is mechanistically associated with α1- 
antagonists such as tamsulosin HCl. The incidence of orthostat-
ic hypotension was not different between FDC and individual 
drug administration in both studies (Table 4). The overall inci-
dence of orthostatic hypotension was 40.0% in the fasted study 
and 17.1% in the fed study. This difference can be explained by 
the food effect on the exposure of tamsulosin HCl. However, 
there were no manifest symptoms or signs related to orthostatic 
hypotension, nor any subjects with SBP <90 mmHg in standing 
position. Although headache and dizziness were reported, these 
AEs were not associated with orthostatic hypotension in our 
studies. Although it has been reported that tamsulosin HCl, a 
selective antagonist of α1A-adrenoceptors, which are not present 
in the blood vessels, shows less frequent orthostatic hypotension 
than conventional α1- antagonists,[17-19] our results show that 
administering tamsulosin HCl after meal is preferred to taking 
in fasted state in order to prevent orthostatic hypotension.   
  Our results also showed hypotensive potential of concomitant 
administration of tadalafil and tamsulosin HCl, but SBP was 
relatively less influenced than DBP, and dizziness, a symptom 
related to the decrease of DBP, was reported in 2 subjects (5.8%) 
only in fed study. Because it has been known that the exposure 
of tadalafil is not affected by fed condition and our analysis 
was post-hoc comparison of the two individual studies, pla-
cebo controlled systematic design of clinical trials is required 
to reveal the influence of tadalafil and tamsulosin HCl on the 
changes of vital signs and orthostatic hypotension. Although 
there were no subjects with a standing SBP <90 mmHg and no 
syncope following co-administration of investigational products 
was reported, paying attention to the changes of vital sign when 
tadalafil and tamsulosin HCl are co-prescribed in old-aged pa-
tients is desirable.
  There is a limitation of this article. Both studies were con-
ducted individually, not designed as crossover studies, therefore 
the result of evaluating statistically food effect could not be con-
cluded corroboratively. Designing adequate study is required for 
more accurate evaluation for the food effect of FDC on pharma-
cokinetics and safety.
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